Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christie Mina

Neurological Surgery Greenville, SC Medical Doctor

NPI 1194737726 CMS profile 190472

3 Saint Francis Dr, Suite 490, Greenville, SC 29601

Open in the dashboard

General payments

$13,475

176 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christie Mina of Greenville, SC is reported in the CMS Open Payments database as having received $13,475 across 176 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,985 26
2024 General $1,399 25
2023 General $1,338 20
2022 General $1,351 18
2021 General $1,242 21
2020 General $3,999 24
2019 General $2,160 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christie Mina
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Christie Mina were reported at $1,985. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Christie Mina Neurological Surgery median Middle half National median
2019 $2,160 $582 $138–$3,006 $163
2020 $3,999 $294 $76–$2,174 $114
2021 $1,242 $387 $105–$2,432 $132
2022 $1,351 $542 $139–$2,989 $149
2023 $1,338 $534 $145–$2,697 $160
2024 $1,399 $574 $155–$3,046 $164
2025 $1,985 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $3,526 60 payments
  2. Alphatec Spine, Inc $3,515 7 payments
  3. Boston Scientific Corporation $1,802 29 payments
  4. Medtronic USA, Inc. $1,152 31 payments
  5. Nevro Corp. $506 7 payments
  6. Intrinsic Therapeutics $469 5 payments
  7. Globus Medical, Inc. $425 8 payments
  8. DePuy Synthes Sales Inc. $406 5 payments
  9. Abbott Laboratories $370 6 payments
  10. Spine Wave, Inc. $226 2 payments
  11. Other $1,077 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,293 172 payments
  2. Travel and Lodging $3,182 4 payments
Products named General payments · program years 2019–2025
  1. Other - Miscellaneous $3,364 6 payments
  2. VANTA ADAPTIVESTIM $841 9 payments
  3. CATALYFT PL EXPANDABLE INTERBODY SYSTEM $743 14 payments
  4. SPECTRA WAVEWRITER $686 12 payments
  5. INCEPTIV $508 6 payments
  6. BARRICAID ACD (ANNULAR CLOSURE DEVICE) Annular Closure Device $469 5 payments
  7. BARRICAID ACD (ANNULAR CLOSURE DEVICE) Annular Closure Device $469 5 payments
  8. WaveWriter Alpha Prime 16 $431 6 payments
  9. ANTERALIGN SPINAL SYSTEM WITH TITAN NANOLOCK SURFACE TECHNOLOGY $389 6 payments
  10. ADAPTIVESTIM $340 4 payments
  11. Other $5,322 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

866

Median for Neurosurgery: 83

Drug cost

$13,233

Median for Neurosurgery: $872

Branded share of claims

6.6%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 233 $3,429
Celecoxib Generic 40 $2,965
Naloxone Hcl Generic 26 $1,680
Methocarbamol Generic 109 $1,452
Pregabalin Generic 20 $543
Baclofen Generic 41 $542
Oxycodone Hcl Generic 104 $475
Duloxetine Hcl Generic 44 $419
Diclofenac Sodium Generic 44 $396
Tizanidine Hcl Generic 27 $324

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 78 billing codes

Paid by Medicare

$357,476

Medicare's payments for the services billed

Medicare patients

699

Average age 74

Services billed

2,235

446 women, 253 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 30%
Depression 30%
Diabetes 28%
Chronic kidney disease 24%
Osteoporosis 23%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

176 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record